Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

IGF-1 lr3

Long R3 IGF-1, LR3-IGF-1, Insulin-like Growth Factor-1 Long Arg3

Quick Stats
Studies 41
Trials 0
Score 3
1999 pubmed 33 citations

The modulation of gonadotrophic hormone action on the ovary by paracrine and autocrine factors.

Campbell. B K BK

Key Findings

  • IGF‑1 LR3 stimulates proliferation and hormone production in granulosa and theca cells in vitro
  • IGF‑1 LR3 enhances follicle development and ovarian estrogen/androgen secretion in vivo in sheep
  • TGF‑alpha and EGF increase cell growth but suppress hormone output and can cause follicle atresia
  • Inhibin A boosts hormone production in vitro but reduces ovarian steroid levels in vivo due to lower FSH

Practical Outcomes

  • IGF‑1 LR3 may have the potential to support ovarian health and hormone balance, but the findings are from sheep and focus on reproductive tissue, so they don’t directly translate into dosing or performance protocols for muscle or longevity. Biohackers should view this as mechanistic confirmation of IGF‑1’s proliferative effects, not as a new actionable regimen, and remain cautious about species differences and hormonal side‑effects.

Summary

The study shows that an IGF‑1 LR3‑like molecule can boost the growth and hormone output of ovarian cells in sheep, helping follicles develop and increasing estrogen and androgen levels. Other factors like TGF‑alpha and EGF also affect these cells but tend to suppress hormone production, while inhibin A has mixed effects. These results confirm IGF‑1’s role in promoting cell proliferation and hormone synthesis, but they’re specific to the ovary and were done in animals, not humans.

Abstract

It has been hypothesized that the physiological basis of follicle selection is the differential expression of factors, which modulate the action of gonadotrophins on follicular cells, at key points during the process of follicle development. The aim of this research was to test this hypothesis by identifying factors that can enhance or attenuate the action of the gonadotrophins in stimulating follicle development using both in vivo and in vitro models. Experiments in vivo utilized sheep with an ovarian autotransplant to allow intra-arterial infusion of putative local factors and exposure of the ovary to high local concentrations. Experiments in vitro utilized physiological serum-free cell culture systems for both granulosa and theca cells that allow gonadotrophin-induced differentiation in vitro. The putative local factors tested included insulin-like growth factor-I (IGF-I LR3 analogue), transforming growth factor alpha (TGF alpha) or epidermal growth factor (EGF) and inhibin A. IGF-I stimulated both cellular proliferation and hormone production by both granulosa and theca cells in vitro and similarly stimulated ovarian follicle development and ovarian androgen and oestradiol secretion in vivo. Both TGF alpha and EGF stimulated granulosa and thecal cell proliferation in vitro in a dose-responsive manner and concomitantly inhibited hormone production, whereas intra-arterial infusion of TGF alpha in vivo resulted in induction of atresia in large antral follicles and an acute fall in ovarian hormone secretion. Inhibin A in vitro augmented gonadotrophin stimulated androgen and oestradiol production by thecal and granulosa cells, respectively, but had no effect on cell number. Paradoxically, intra-arterial infusion of inhibin A resulted in an acute depression in ovarian steroid secretion. This depression, however, was also associated with an acute depression in circulating FSH concentrations. In conclusion, these data provide strong support for the hypothesis that factors can modulate the action of gonadotrophins on follicular cells to augment (IGF-I, inhibin A) or inhibit (TGF alpha/EGF) granulosa and thecal cell differentiation. The challenge for the future in this area of research is to understand how these factors interact to enable one follicle to be selected from an ovulatory cohort.

Study Information

Provider

pubmed

Year

1999

Date

1999-08-01T00:00:00.000Z

DOI

10.1046/j.1439-0264.1999.00200.x

Citations

33

References

18